Analysts Set Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Price Target at $16.67

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has been given a consensus rating of “Moderate Buy” by the five brokerages that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $16.67.

A number of analysts have recently commented on ATRA shares. HC Wainwright reiterated a “neutral” rating on shares of Atara Biotherapeutics in a research report on Wednesday, August 21st. TD Cowen upgraded Atara Biotherapeutics to a “strong-buy” rating in a research note on Friday, November 29th. Finally, Canaccord Genuity Group upped their price target on shares of Atara Biotherapeutics from $13.00 to $21.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC lifted its stake in shares of Atara Biotherapeutics by 9.5% in the 3rd quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock worth $380,000 after acquiring an additional 4,043 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Atara Biotherapeutics during the 2nd quarter worth approximately $53,000. FMR LLC raised its stake in shares of Atara Biotherapeutics by 41.7% during the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock worth $204,000 after buying an additional 7,381 shares in the last quarter. State Street Corp lifted its holdings in shares of Atara Biotherapeutics by 52.3% in the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock valued at $182,000 after buying an additional 7,680 shares during the period. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Atara Biotherapeutics in the second quarter valued at approximately $79,000. 70.90% of the stock is currently owned by hedge funds and other institutional investors.

Atara Biotherapeutics Stock Down 1.5 %

NASDAQ ATRA opened at $10.35 on Friday. Atara Biotherapeutics has a 52 week low of $6.50 and a 52 week high of $39.50. The firm has a 50 day moving average of $10.60 and a two-hundred day moving average of $9.65. The stock has a market capitalization of $59.62 million, a PE ratio of -0.40 and a beta of 0.55.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share for the quarter, topping the consensus estimate of ($3.77) by $0.84. The business had revenue of $40.19 million for the quarter, compared to analysts’ expectations of $23.00 million. During the same quarter in the previous year, the firm earned ($16.50) EPS. On average, equities research analysts expect that Atara Biotherapeutics will post -12.12 earnings per share for the current fiscal year.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.